TIL Therapy: A New Melanoma Treatment 30 Years in the Making
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
Author:
Neha J. Pancholi, PhD
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
Researchers discussed AI's impact on the diagnosis and treatment of cancer at the AACR Annual Meeting 2024.
The latest installment of this quarterly series highlights innovative research approaches reported at the AACR Annual Meeting 2024.
At the AACR Annual Meeting 2024, researchers discussed innovative approaches to decipher the complexities of tumor ecosystems.
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
Experts discussed "Discovery Science in Early Cancer Biology and Interception" at a plenary during the AACR Annual Meeting 2024.
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
Patricia M. LoRusso and Stacy Shord discuss dosage optimization's current state and how the FDA-AACR workshop will move the...
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug...
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts...